M. Haas, S. Meehan, T. Karrison, and B. Spargo, Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from, 1976.

J. Hanko, R. Mullan, O. Rourke, D. Mcnamee, P. Maxwell et al., The changing pattern of adult primary glomerular disease, Nephrology Dialysis Transplantation, vol.24, issue.Suppl 2, pp.3050-3054, 2009.
DOI : 10.1093/ndt/gfn554

S. Hogan, K. Muller, J. Jennette, and R. Falk, A review of therapeutic studies of idiopathic membranous glomerulopathy, American Journal of Kidney Diseases, vol.25, issue.6, pp.862-875, 1995.
DOI : 10.1016/0272-6386(95)90568-5

D. Kerjaschki and M. Farquhar, Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats, Journal of Experimental Medicine, vol.157, issue.2, pp.667-686, 1983.
DOI : 10.1084/jem.157.2.667

H. Debiec, V. Guigonis, B. Mougenot, F. Decobert, J. Haymann et al., Antenatal Membranous Glomerulonephritis Due to Anti???Neutral Endopeptidase Antibodies, New England Journal of Medicine, vol.346, issue.26
DOI : 10.1056/NEJMoa012895

L. Beck, . Jr, R. Bonegio, G. Lambeau, D. Beck et al., Mtype phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N
URL : https://hal.archives-ouvertes.fr/hal-00417718

H. Debiec, F. Lefeu, M. Kemper, P. Niaudet, G. Deschênes et al., Early-Childhood Membranous Nephropathy Due to Cationic Bovine Serum Albumin, New England Journal of Medicine, vol.364, issue.22, pp.2101-2110, 2011.
DOI : 10.1056/NEJMoa1013792

M. Hladunewich, S. Troyanov, J. Calafati, and D. Cattran, The Natural History of the Non-Nephrotic Membranous Nephropathy Patient, Clinical Journal of the American Society of Nephrology, vol.4, issue.9, pp.1417-1422, 2009.
DOI : 10.2215/CJN.01330209

A. Schieppati, L. Mosconi, A. Perna, G. Mecca, T. Bertani et al., Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy, New England Journal of Medicine, vol.329, issue.2, pp.85-89, 1993.
DOI : 10.1056/NEJM199307083290203

N. Polanco, E. Gutiérrez, A. Covarsí, F. Ariza, A. Carreño et al., Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy, Journal of the American Society of Nephrology, vol.21, issue.4, pp.697-704, 2010.
DOI : 10.1681/ASN.2009080861

L. Reichert, R. Koene, and J. Wetzels, Prognostic factors in idiopathic membranous nephropathy, American Journal of Kidney Diseases, vol.31, issue.1, pp.1-11, 1998.
DOI : 10.1053/ajkd.1998.v31.pm9428445

Y. Pei, D. Cattran, and C. Greenwood, Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis, Kidney International, vol.42, issue.4, pp.960-966, 1992.
DOI : 10.1038/ki.1992.374

D. Cattran, Y. Pei, C. Greenwood, C. Ponticelli, P. Passerini et al., Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications, Kidney International, vol.51, issue.3, pp.901-907, 1997.
DOI : 10.1038/ki.1997.127

L. Reichert, R. Koene, and J. Wetzels, Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy, J. Am. Soc. Nephrol. déc, vol.6, issue.6, pp.1666-1669, 1995.

A. Branten, P. Du-buf-vereijken, I. Klasen, F. Bosch, G. Feith et al., Urinary Excretion of ??2-Microglobulin and IgG Predict Prognosis in Idiopathic Membranous Nephropathy: A Validation Study, Journal of the American Society of Nephrology, vol.16, issue.1, pp.169-174, 2005.
DOI : 10.1681/ASN.2004040287

J. Van-den-brand, J. Hofstra, and J. Wetzels, Low-Molecular-Weight Proteins as Prognostic Markers in Idiopathic Membranous Nephropathy, Clinical Journal of the American Society of Nephrology, vol.6, issue.12, pp.2846-2853, 2011.
DOI : 10.2215/CJN.04020411

J. Van-den-brand, J. Hofstra, and J. Wetzels, Prognostic Value of Risk Score and Urinary Markers in Idiopathic Membranous Nephropathy, Clinical Journal of the American Society of Nephrology, vol.7, issue.8, pp.1242-1248, 2012.
DOI : 10.2215/CJN.00670112

S. Troyanov, C. Wall, J. Miller, J. Scholey, and D. Cattran, Idiopathic membranous nephropathy: Definition and relevance of a partial remission, Kidney International, vol.66, issue.3, pp.1199-1205, 2004.
DOI : 10.1111/j.1523-1755.2004.00873.x

C. Baigent, M. Landray, C. Reith, J. Emberson, D. Wheeler et al., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, The Lancet, vol.377, issue.9784, pp.2181-2192, 2011.
DOI : 10.1016/S0140-6736(11)60739-3

F. Sarasin and J. Schifferli, Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy, Kidney International, vol.45, issue.2, pp.578-585, 1994.
DOI : 10.1038/ki.1994.75

S. Lionaki, V. Derebail, S. Hogan, S. Barbour, T. Lee et al., Venous Thromboembolism in Patients with Membranous Nephropathy, Clinical Journal of the American Society of Nephrology, vol.7, issue.1, pp.43-51, 2012.
DOI : 10.2215/CJN.04250511

D. Ducloux, C. Bresson-vautrin, and J. Chalopin, Use of pentoxifylline in membranous nephropathy, The Lancet, vol.357, issue.9269, pp.1672-1673, 2001.
DOI : 10.1016/S0140-6736(00)04830-3

N. Braun, J. Frank, H. Biesalski, and T. Risler, Antioxidative Treatment Retards Progression of Idiopathic Membranous Nephropathy, Nephron, vol.86, issue.2, pp.208-209, 2000.
DOI : 10.1159/000045751

D. Cattran, T. Delmore, R. J. Cole, E. Cardella, C. Charron et al., A Randomized Controlled Trial of Prednisone in Patients with Idiopathic Membranous Nephropathy, New England Journal of Medicine, vol.320, issue.4
DOI : 10.1056/NEJM198901263200403

. Med, 26 janv, pp.210-215, 1989.

C. Ponticelli, P. Zucchelli, E. Imbasciati, L. Cagnoli, C. Pozzi et al., Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy, New England Journal of Medicine, vol.310, issue.15
DOI : 10.1056/NEJM198404123101503

C. Ponticelli, P. Zucchelli, P. Passerini, B. Cesana, F. Locatelli et al., A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy, Kidney International, vol.48, issue.5, pp.1600-1604, 1995.
DOI : 10.1038/ki.1995.453

C. Ponticelli, P. Altieri, F. Scolari, P. Passerini, D. Roccatello et al., A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy, J. Am. Soc. Nephrol. mars, vol.9, issue.3, pp.444-450, 1998.

V. Jha, A. Ganguli, T. Saha, H. Kohli, K. Sud et al., A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy, Journal of the American Society of Nephrology, vol.18, issue.6, pp.1899-1904, 2007.
DOI : 10.1681/ASN.2007020166

Y. Chen, A. Schieppati, G. Cai, X. Chen, J. Zamora et al., Immunosuppression for Membranous Nephropathy: A Systematic Review and Meta-Analysis of 36 Clinical Trials, Clinical Journal of the American Society of Nephrology, vol.8, issue.5, pp.787-796, 2013.
DOI : 10.2215/CJN.07570712

A. Howman, T. Chapman, M. Langdon, C. Ferguson, D. Adu et al., Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial, The Lancet, vol.381, issue.9868, pp.744-751, 2013.
DOI : 10.1016/S0140-6736(12)61566-9

M. Praga, V. Barrio, G. Juárez, and J. Luño, Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial, Kidney International, vol.71, issue.9, pp.924-930, 2007.
DOI : 10.1038/sj.ki.5002215

J. Ballarin, R. Poveda, A. J. Pérez, L. Calero, F. Grinyó et al., Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study, Nephrology Dialysis Transplantation, vol.22, issue.11, pp.3196-3201, 2007.
DOI : 10.1093/ndt/gfm366

B. Dussol, S. Morange, S. Burtey, M. Indreies, E. Cassuto et al., Mycophenolate Mofetil Monotherapy in Membranous Nephropathy: A 1-Year Randomized Controlled Trial, American Journal of Kidney Diseases, vol.52, issue.4
DOI : 10.1053/j.ajkd.2008.04.013

T. Chan, A. Lin, S. Tang, J. Qian, M. Lam et al., Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome, Nephrology, vol.35, issue.6, pp.576-581, 2007.
DOI : 10.1093/ndt/gfh312

A. Branten, P. Du-buf-vereijken, M. Vervloet, and J. Wetzels, Mycophenolate Mofetil in Idiopathic Membranous Nephropathy: A Clinical Trial With Comparison to a Historic Control Group Treated With Cyclophosphamide, American Journal of Kidney Diseases, vol.50, issue.2, pp.248-256, 2007.
DOI : 10.1053/j.ajkd.2007.05.015

M. Ahuja, D. Goumenos, J. Shortland, A. Gerakis, and C. Brown, Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?, American Journal of Kidney Diseases, vol.34, issue.3, pp.521-529, 1999.
DOI : 10.1016/S0272-6386(99)70081-8

G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli et al., Rituximab for idiopathic membranous nephropathy, The Lancet, vol.360, issue.9337, pp.923-924, 2002.
DOI : 10.1016/S0140-6736(02)11042-7

P. Ruggenenti, C. Chiurchiu, V. Brusegan, M. Abbate, A. Perna et al., Rituximab in Idiopathic Membranous Nephropathy: A One-Year Prospective Study, Journal of the American Society of Nephrology, vol.14, issue.7, pp.1851-1857, 2003.
DOI : 10.1097/01.ASN.0000071511.35221.B3

F. Fervenza, F. Cosio, S. Erickson, U. Specks, A. Herzenberg et al., Rituximab treatment of idiopathic membranous nephropathy, Kidney International, vol.73, issue.1, pp.117-125, 2008.
DOI : 10.1038/sj.ki.5002628

A. Segarra, M. Praga, N. Ramos, N. Polanco, I. Cargol et al., Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients, Clinical Journal of the American Society of Nephrology, vol.4, issue.6, pp.1083-1088, 2009.
DOI : 10.2215/CJN.06041108

P. Cravedi, M. Sghirlanzoni, M. Marasà, A. Salerno, G. Remuzzi et al., Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study, American Journal of Nephrology, vol.5, issue.5, pp.461-468, 2011.
DOI : 10.2215/CJN.05080610

P. Ruggenenti, P. Cravedi, A. Chianca, A. Perna, B. Ruggiero et al., Rituximab in Idiopathic Membranous Nephropathy, Journal of the American Society of Nephrology, vol.23, issue.8, pp.1416-1425, 2012.
DOI : 10.1681/ASN.2012020181

C. Ponticelli, P. Passerini, M. Salvadori, C. Manno, B. Viola et al., A Randomized Pilot Trial Comparing Methylprednisolone Plus a Cytotoxic Agent Versus Synthetic Adrenocorticotropic Hormone in Idiopathic Membranous Nephropathy, American Journal of Kidney Diseases, vol.47, issue.2, pp.233-240, 2006.
DOI : 10.1053/j.ajkd.2005.10.016

N. Muirhead, Management of idiopathic membranous nephropathy: Evidence-based recommendations, Kidney International, vol.55, pp.47-55, 1999.
DOI : 10.1046/j.1523-1755.1999.07007.x

R. Glassock, The treatment of idiopathic membranous nephropathy: A dilemma or a conundrum?, American Journal of Kidney Diseases, vol.44, issue.3, pp.562-566, 2004.
DOI : 10.1016/S0272-6386(04)00868-6

D. Buf-vereijken, P. Branten, A. Wetzels, and J. , Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy, American Journal of Kidney Diseases, vol.46, issue.6, pp.1012-1029, 2005.
DOI : 10.1053/j.ajkd.2005.08.020

J. Hofstra and J. Wetzels, Management of patients with membranous nephropathy, Nephrology Dialysis Transplantation, vol.25, issue.1
DOI : 10.1093/ndt/gfp390

J. Radhakrishnan and D. Cattran, The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines???application to the individual patient, Kidney International, vol.82, issue.8, pp.840-856, 2012.
DOI : 10.1038/ki.2012.280

J. Hofstra, A. Branten, J. Wirtz, T. Noordzij, P. Du-buf-vereijken et al., Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial, Nephrology Dialysis Transplantation, vol.56, issue.4, pp.129-136, 2010.
DOI : 10.1159/000186178

B. Marx and M. Marx, Prognosis of idiopathic membranous nephropathy: A methodologic meta-analysis, Kidney International, vol.51, issue.3, pp.873-879, 1997.
DOI : 10.1038/ki.1997.123

J. Hofstra and J. Wetzels, Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands, Nephrology Dialysis Transplantation, vol.74, issue.274, pp.3534-3538, 2008.
DOI : 10.1056/NEJM198901263200403

S. Aaltonen and E. Honkanen, Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy, Nephrology Dialysis Transplantation, vol.65, issue.4, pp.2871-2877, 2011.
DOI : 10.1111/j.1523-1755.2004.00518.x

E. Mcquarrie, C. Stirling, and C. Geddes, Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy, Nephrology Dialysis Transplantation, vol.50, issue.3, pp.235-242, 2012.
DOI : 10.1053/j.ajkd.2007.06.003

M. Cabana, C. Rand, N. Powe, A. Wu, M. Wilson et al., Why Don't Physicians Follow Clinical Practice Guidelines? A Framework for Improvement, Pediatric Research, vol.45, issue.4, Part 2 of 2, pp.1458-1465, 1999.
DOI : 10.1203/00006450-199904020-00719

F. Saillour-glenisson and P. Michel, Individual and collective facilitators of and barriers to the use of clinical practice guidelines by physicians: a literature review, Rev Epidemiol Sante Publique. févr, vol.51, issue.1, pp.65-80, 2003.